Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Exploratory Clinical Study of Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia

NCT07933146 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Exploratory Clinical Study of Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
October 31, 2028
Enrollment
96 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Hetrombopag sequential group ExperimentalHetrombopag and recombinant human thrombopoietin
  • Recombinant human thrombopoietin group ExperimentalRecombinant Human Thrombopoietin

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Response rate Up to 6 weeks

    Proportion of participants achieving treatment response

Lead sponsor's other trials

The First Affiliated Hospital of Zhengzhou University, most recent start first.

Similar trials

Same condition (Thrombocytopenia) and phase, most recent start first.